Wellgistics Launches Forzet™ Through 6,500-Pharmacy Network to Address GLP-1 Muscle Loss
Wellgistics Health launched Forzet™ medical food to preserve muscle loss from GLP-1 therapies, distributing it OTC through its 6,500-pharmacy EinsteinRx network. The GLP-1 agonist market is projected to grow from $70 billion in 2025 to $201 billion by 2030, driving demand for muscle-preserving solutions.
1. Forzet Medical Food Launch
Wellgistics introduced Forzet™, a proprietary medical food formulated to manage muscle loss associated with GLP-1 agonist weight-loss therapies such as Ozempic and Wegovy. The formulation has undergone multiple controlled clinical studies in patients with Type 2 diabetes, heart failure and COPD, and is classified as a medical food available OTC without prescription.
2. GLP-1 Market Opportunity
The GLP-1 agonist market is set to expand from $70 billion in 2025 to $201 billion by 2030, driven by rising potency, oral formulations and off-label use by non-obese patients. Muscle loss remains a key side effect limiting therapy adherence, creating a clear niche for adjunct solutions backed by clinical data.
3. Distribution and Integration Strategy
Forzet will roll out through Wellgistics’ affiliated pharmacy and select network members, leveraging EinsteinRx™ AI-powered pop-ups at point-of-sale to drive physician and pharmacist recommendations. The company also plans to embed Forzet into its direct-to-consumer telehealth platform and in-store pharmacy services to build loyalty and capture recurring demand.